Arazit IR Day, December 2026, Seoul and online. Request an invitation

Samsung Biologics

삼성바이오로직스KOSPI 207940Biopharma

Samsung Biologics is a contract development and manufacturing organization that develops and produces biopharmaceuticals for pharmaceutical clients, with campuses in Songdo, Incheon, and in Rockville in the United States. Its 2025 business report describes a corporate spin-off that left it focused on a pure-play contract manufacturing model.

Investor relations site ↗

Earnings

21 Oct 2026Earnings Release 2026 Q3Samsung Biologics' third quarter 2026 earnings deck, with revenue of KRW 1,490 billion, operating profit of KRW 640 billion and full-year revenue growth guidance raised to 20%. It also covers contract volume, plant ramp-up, the PolyPeptide tender offer and the rights offering.Samsung BiologicsPDF, 18 pp

Transaction

28 Aug 2026Rights OfferingSamsung Biologics' investor presentation on its 2026 rights offering, setting out planned uses of funds through 2034. It itemizes the PolyPeptide acquisition at KRW 2.71 trillion, Plant 6, Plant 7, Bio Campus III and United States plant expansion.Samsung BiologicsPDF, 20 pp

Transcript

28 Aug 2026Samsung Biologics Conference Call Transcript (8/28)The English transcript of the call in which Samsung Biologics' management explained the paid-in capital increase of about KRW 3 trillion. It is useful for how the company justifies the funding need, including the alternatives it weighed and concerns over shareholder dilution.Samsung BiologicsPDF, 12 pp

Annual report

UndatedBusiness Report, The 15th accounting PeriodSamsung Biologics' English business report for fiscal 2025, with the CEO's message, company history, board details, operations, major shareholders and consolidated and separate financial statements. The CEO's message explains the move to a pure-play contract manufacturing model.Samsung BiologicsPDF, 51 pp

Governance report

Undated2025 Corporate Governance ReportSamsung Biologics' English corporate governance report under KOSPI disclosure rules, covering shareholders, the board and audit systems. It is the most detailed company source on how the board operates, since no Value-up plan was found for this company.Samsung BiologicsPDF, 74 pp